OLMA
insider transactionsOlema Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-267.3K
0 buy · 267.3K sell
Net value · 365d
-$7.4M
$0 in · $7.4M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
12
0 buy · 267.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
24.1K sh
Own New
-
Grant·A
Director
$0
2.9K sh
Own New
-
Exercise·M
CHIEF LEGAL OFFICER
$0
25.0K sh
Own +6%
-
Sell·S
CHIEF LEGAL OFFICER
$5.8K
233 sh · $24.69
Own -100%
-
Sell·S
CHIEF LEGAL OFFICER
$600.6K
24.8K sh · $24.25
Own -99%
-
Exercise·M
CHIEF LEGAL OFFICER
$109.2K
25.0K sh · $4.37
Own New
-
Exercise·M
CHIEF LEGAL OFFICER
$0
15.0K sh
Own +4%
-
Sell·S
CHIEF LEGAL OFFICER
$345.1K
15.0K sh · $23.01
Own -100%
-
Exercise·M
CHIEF LEGAL OFFICER
$65.5K
15.0K sh · $4.37
Own New
-
Grant·A
CHIEF MEDICAL OFFICER
$0
106.2K sh
Own New
-
Grant·A
CHIEF MEDICAL OFFICER
$0
250.0K sh
Own New
-
Grant·A
CH. DISCOV. & NON-CLIN DEV OFF
$0
106.2K sh
Own New
-
Grant·A
CH. DISCOV. & NON-CLIN DEV OFF
$0
250.0K sh
Own New
-
Grant·A
CHIEF LEGAL OFFICER
$0
56.2K sh
Own New
-
Grant·A
CHIEF LEGAL OFFICER
$0
220.0K sh
Own New
-
Grant·A
Sean Bohen KEY
PRESIDENT AND CEO
$0
275.0K sh
Own New
-
Grant·A
Sean Bohen KEY
PRESIDENT AND CEO
$0
850.0K sh
Own New
-
Grant·A
VP of Finance and Controller
$0
29.2K sh
Own New
-
Grant·A
VP of Finance and Controller
$0
11.7K sh
Own +261%
-
Sell·S
Director
$268.8K
10.0K sh · $26.88
Own -1%
-
Sell·S
CH. OPERATING & FINANCIAL OFF.
$2.9M
100.0K sh · $28.73
Own -42%
-
Exercise·M
CH. DISCOV. & NON-CLIN DEV OFF
$0
50.0K sh
Own New
-
Sell·S
CH. DISCOV. & NON-CLIN DEV OFF
$1.0M
35.0K sh · $28.99
Own -6%
-
Sell·S
CH. DISCOV. & NON-CLIN DEV OFF
$428.9K
15.0K sh · $28.60
Own -3%
-
Exercise·M
CH. DISCOV. & NON-CLIN DEV OFF
$243.5K
50.0K sh · $4.87
Own +9%
-
Sell·S
Director
$101.6K
3.5K sh · $29.12
Own -0%
-
Exercise·M
CH. DISCOV. & NON-CLIN DEV OFF
$0
50.0K sh
Own +100%
-
Sell·S
CH. DISCOV. & NON-CLIN DEV OFF
$5.7K
200 sh · $28.49
Own -0%
-
Sell·S
CH. DISCOV. & NON-CLIN DEV OFF
$1.4M
49.8K sh · $27.60
Own -8%
-
Exercise·M
CH. DISCOV. & NON-CLIN DEV OFF
$243.5K
50.0K sh · $4.87
Own +9%
-
Sell·S
CH. OPERATING & FINANCIAL OFF.
$107.1K
3.8K sh · $28.01
Own -2%
-
Sell·S
CH. DISCOV. & NON-CLIN DEV OFF
$283.4K
10.0K sh · $28.34
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 28, 2026 | Prakash Raman | Grant A | 24.1K | $0 |
| Apr 28, 2026 | Prakash Raman | Grant A | 2.9K | $0 |
| Mar 4, 2026 | Shawnte Mitchell | Exercise M | 25.0K | $0 |
| Mar 4, 2026 | Shawnte Mitchell | Sell S | 233 | $5.8K |
| Mar 4, 2026 | Shawnte Mitchell | Sell S | 24.8K | $600.6K |
| Mar 4, 2026 | Shawnte Mitchell | Exercise M | 25.0K | $109.2K |
| Mar 3, 2026 | Shawnte Mitchell | Exercise M | 15.0K | $0 |
| Mar 3, 2026 | Shawnte Mitchell | Sell S | 15.0K | $345.1K |
| Mar 3, 2026 | Shawnte Mitchell | Exercise M | 15.0K | $65.5K |
| Feb 2, 2026 | Naseem Zojwalla | Grant A | 106.2K | $0 |
| Feb 2, 2026 | Naseem Zojwalla | Grant A | 250.0K | $0 |
| Feb 2, 2026 | David C. Myles | Grant A | 106.2K | $0 |
| Feb 2, 2026 | David C. Myles | Grant A | 250.0K | $0 |
| Feb 2, 2026 | Shawnte Mitchell | Grant A | 56.2K | $0 |
| Feb 2, 2026 | Shawnte Mitchell | Grant A | 220.0K | $0 |
| Feb 2, 2026 | Sean Bohen KEY | Grant A | 275.0K | $0 |
| Feb 2, 2026 | Sean Bohen KEY | Grant A | 850.0K | $0 |
| Feb 2, 2026 | Sasha Lu Austin | Grant A | 29.2K | $0 |
| Feb 2, 2026 | Sasha Lu Austin | Grant A | 11.7K | $0 |
| Jan 20, 2026 | Cyrus Harmon | Sell S | 10.0K | $268.8K |
| Jan 15, 2026 | Shane William Charles Kovacs | Sell S | 100.0K | $2.9M |
| Jan 14, 2026 | David C. Myles | Exercise M | 50.0K | $0 |
| Jan 14, 2026 | David C. Myles | Sell S | 35.0K | $1.0M |
| Jan 14, 2026 | David C. Myles | Sell S | 15.0K | $428.9K |
| Jan 14, 2026 | David C. Myles | Exercise M | 50.0K | $243.5K |
| Jan 14, 2026 | Cyrus Harmon | Sell S | 3.5K | $101.6K |
| Jan 13, 2026 | David C. Myles | Exercise M | 50.0K | $0 |
| Jan 13, 2026 | David C. Myles | Sell S | 200 | $5.7K |
| Jan 13, 2026 | David C. Myles | Sell S | 49.8K | $1.4M |
| Jan 13, 2026 | David C. Myles | Exercise M | 50.0K | $243.5K |
| Jan 13, 2026 | Shane William Charles Kovacs | Sell S | 3.8K | $107.1K |
| Jan 12, 2026 | David C. Myles | Sell S | 10.0K | $283.4K |
About OLMA insider trading
This page tracks insider transactions for Olema Pharmaceuticals, Inc. (OLMA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.